NewslettersNeural Cell News Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects By Jamie Kang - October 5, 2022 0 Alzamend Neuro, Inc. announced it has dosed its first healthy adult subject in its Phase IIA multiple ascending dose study of AL001 in subjects with dementia related to Alzheimer’s. [Alzamend Neuro, Inc.] Press Release